LivaNova (NASDAQ:LIVN) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

LIVN has been the subject of a number of other research reports. Needham & Company LLC reiterated a buy rating and issued a $72.00 price target on shares of LivaNova in a report on Wednesday, March 20th. Mizuho reiterated a buy rating and issued a $75.00 price target on shares of LivaNova in a report on Wednesday, March 27th. Robert W. Baird increased their price target on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a report on Thursday, February 22nd. Finally, Barclays lifted their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a research report on Monday, February 26th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $64.40.

LivaNova Stock Down 2.5 %

LIVN stock opened at $51.87 on Wednesday. LivaNova has a one year low of $42.75 and a one year high of $59.86. The stock has a market capitalization of $2.80 billion, a PE ratio of 162.10 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. The company has a fifty day moving average of $53.51 and a 200-day moving average of $50.53.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.77 by $0.10. The company had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the business earned $0.81 EPS. As a group, analysts expect that LivaNova will post 3.01 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC acquired a new position in LivaNova during the second quarter worth about $46,000. Point72 Middle East FZE acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $72,000. Headlands Technologies LLC acquired a new position in shares of LivaNova in the third quarter valued at approximately $72,000. Picton Mahoney Asset Management acquired a new position in shares of LivaNova in the third quarter valued at approximately $91,000. Finally, Guggenheim Capital LLC acquired a new position in shares of LivaNova in the first quarter valued at approximately $215,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.